Search Results

Featured Stories

Toggle

Showing 10 of 235 results

Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clini

Four posters examine the long-term efficacy, safety, and tolerability of AUSTEDO in patients with tardive dyskinesia and a review of clinical outcome measures in schizophrenia TEL AVIV, Israel &...

Teva to Present New Data at The MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience Eval

Additional data to be presented examining the safety and tolerability of AUSTEDO during periods of titration and maintenance

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at the MDS Virtual Congress 2020 and Psyc

JERUSALEM & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Neuroscience, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new study data on AUSTEDO® (deutetrabenazine) will be presented at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and during the Psych Congress 2020 Virtual Experience.

China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia i

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the China National Medical Products Administration (NMPA) has approved AUSTEDO® (Deutetrabenazine Tablets) for the...

Teva to Present AUSTEDO® (deutetrabenazine) Tablets Data at the American Psychiatric Association 2018 Ann

Three abstracts evaluate the long-term safety and efficacy of AUSTEDO ® (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults In addition, new health economics data assess...

Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injec

Up to 7-year efficacy, safety and tolerability results from the GALA open-label extension study presented at the 70 th Annual Meeting of the AAN Over seven years, COPAXONE ® 40 mg/mL provides...

Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy

Two platform presentations and 19 posters explore the potential of fremanezumab as an investigational treatment option for the prevention of migraine COPAXONE ® (glatiramer acetate injection) and...

New Survey Highlights Misconceptions about Family Planning among Women with Relapsing Forms of Multiple S

88% of women with RMS were concerned they would not be able to have children, despite studies that show otherwise More, and better, information on family planning options is needed Teva...

Teva Completes Amendment to Credit Facilities

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced amendments to its USD and JPY term loan and revolving credit facilities, providing the company greater flexibility in its...

Teva Announces Completion of Global Women’s Health Divestiture to CVC Capital Partners

Teva to receive $703 million cash proceeds to progress repayment of term loan debt Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has completed the sale of a portfoli...